Episurf Medical (Nasdaq: EPIS B) today announces that the scientific abstract “Clinical results of an individualized mini-metal implant for focal cartilage lesions in the knee” by T. Spalding, C. Stevenson, J. Holz, T. Jung, C. Kösters, M. Lind, L. Konradsen, M. Polacek, P. Verdonk, P. Emans, K. Eriksson and M. Högström has been accepted as a poster presentation at the EORS Congress in Galway, Ireland, which will take place on September 25 - 28, 2018. The abstract focuses on clinical outcomes for patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the mini-metal implant Episealer®.
The abstract shows excellent early clinical results from the treatment of focal full thickness symptomatic cartilage lesions on the femoral condyles or trochlea area of the knee with an individualised metal implant.
"We are happy that the clinical results from the use of Episealer® knee implants will be presented at this meeting. Our technology is clearly generating interest. The patient improvements are being documented and presented, and we are taking very important steps these days”, says Pål Ryfors, CEO of Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.